A. Zacharasiewicz (Wien, Austria), E. Gaillard (Leicester (Leicestershire), United Kingdom)
Introduction
|  |
Genome-wide exploration of inflammation-related proteins and Type 2 asthma
N. Hernandez-Pacheco (Stockholm, Sweden), S. Björkander (Stockholm, Sweden), S. Klevebro (Stockholm, Sweden), S. Kebede Merid (Stockholm, Sweden), A. Kumar (Stockholm, Sweden), I. Mogensen (Stockholm, Sweden), C. Janson (Uppsala, Sweden), L. Palmberg (Stockholm, Sweden), M. Van Hage (Stockholm, Sweden), A. Georgellis (Stockholm, Sweden), A. Bergström (Stockholm, Sweden), I. Kull (Stockholm, Sweden), E. Melén (Stockholm, Sweden)
|    |
Asthma in one breath: metabolic signatures for allergic asthma in children by real-time breath analysis
R. Weber# (Zürich, Switzerland), B. Streckenbach# (Zürich, Switzerland), J. Kaeslin (Zürich, Switzerland), L. Welti (Zürich, Switzerland), D. Inci (Zürich, Switzerland), N. Perkins (Zürich, Switzerland), R. Zenobi (Zürich, Switzerland), S. Micic (Zürich, Switzerland), A. Möller (Zürich, Switzerland)
| |
Evaluation of nocturnal asthma control (NAC-study): Comparative multicenter analysis of subjective and objective methods
S. Weisser (Goettingen, Germany), C. Lex (Goettingen, Germany), L. Roth (Vienna, Austria), K. Kainz (Vienna, Austria), V. Fajgelj (Vienna, Austria), A. Schuetzenmeier (Regensburg, Germany), P. Fischer (Giessen, Germany), V. Gross (Giessen, Germany), M. Reinweber (Vienna, Austria), A. Zacharasiewicz (Vienna, Austria), S. Kerzel (Regensburg, Germany)
| |
ADRB2 Arg16Gly is associated with nocturnal asthma symptoms despite LABA use in two European pediatric asthma studies
S. Vijverberg (Amsterdam, Netherlands), T. Nguyen (Amsterdam, Netherlands), J. Perez-Garcia (San Cristobal de La Laguna, Spain), S. Hashimoto (Amsterdam, Netherlands), A. Neerincx (Amsterdam, Netherlands), M. Abdel-Aziz (Amsterdam, Netherlands), C. Almqvist (Stockholm, Sweden), O. Sardon Prado (San Sebastian, Spain), P. Corcuera (San Sebastian, Spain), J. Korta (San Sebastian, Spain), U. Potocnik (Maribor, Slovenia), M. Kabesch (Regensburg, Germany), A. Kraneveld (Utrecht, Netherlands), M. Pino-Yanes (San Cristobal de La Laguna, Spain), A. Maitland Van Der Zee (Amsterdam, Netherlands)
| |
Dupilumab efficacy in children with uncontrolled type 2 asthma with baseline high/medium ICS dose
J. Maspero ( Buenos Aires, Argentina), M. Antila (Sorocaba, Sao Paulo, Brazil), N. Jain (Gilbert, Arizona, United States), A. Deschildre (Lille, France), L. Bacharier (Nashville, Tennessee, United States), A. Altincatal (Cambridge, Massachusetts, United States), E. Laws (Bridgewater, New Jersey, United States), B. Akinlade (Tarrytown, New York, United States), S. Siddiqui (Tarrytown, New York, United States), J. Jacob-Nara (Bridgewater, New Jersey, United States), Y. Deniz (Tarrytown, New York, United States), P. Rowe (Bridgewater, New Jersey, United States), D. Lederer (Tarrytown, New York, United States), M. Hardin (Cambridge, Massachusetts, United States)
| |
Detection of structural airway changes on computed tomography in paediatric severe asthma
W. van den Bosch (Rotterdam, Netherlands), Q. Lv (Rotterdam, Netherlands), E. Andrinopoulou (Rotterdam, Netherlands), H. Janssens (Rotterdam, Netherlands), P. Ciet (Rotterdam, Netherlands), H. Tiddens (Rotterdam, Netherlands)
| |
Continuous associations of type 2 biomarkers and efficacy of dupilumab in children with uncontrolled, moderate-to-severe asthma
L. Bacharier (Nashville, TN, United States), D. Jackson (Madison, WI, United States), I. Pavord (Oxford, United Kingdom), J. Maspero (Buenos Aires, Argentina), A. Fiocchi (Rome, Italy), X. Mao (Bridgewater, NJ, United States), J. Jacob-Nara (Bridgewater, NJ, United States), Y. Deniz (Tarrytown, NY, United States), E. Laws (Bridgewater, NJ, United States), L. Mannent (Chilly-Mazarin, France), B. Akinlade (Tarrytown, NY, United States), H. Staudinger (Bridgewater, NJ, United States), D. Lederer (Tarrytown, NY, United States), M. Hardin (Cambridge, MA, United States)
| |
Neutrophil granulocytes from Th1-high asthmatics show a reduced chemotactic response to bacterial compound ex vivo
S. Lemmel (Lübeck, Germany), A. Wohlers (Lübeck, Germany), T. Becker (Lübeck, Germany), A. Bachmann (Lübeck, Germany), T. Bahmer (Grosshansdorf, Germany), G. Hansen (Hannover, Germany), E. Von Mutius (München, Germany), K. Rabe (Grosshansdorf, Germany), O. Fuchs (Bern, Switzerland), A. Dittrich (Hannover, Germany), B. Schaub (München, Germany), C. Happle (Hannover, Germany), M. Weckmann (Lübeck, Germany), M. Kopp (Lübeck, Germany)
| |
Late Breaking Abstract - Assessment of the long-term safety and efficacy of dupilumab in children with asthma: LIBERTY ASTHMA EXCURSION
L. Bacharier (Nashville, United States), J. Maspero (Buenos Aires, Argentina), C. Katelaris (Campbelltown, Australia), A. Fiocchi (Rome, Italy), R. Gagnon (Quebec, Canada), I. De Mir-Messa (Barcelona, Spain), T. Guilbert (Cincinnati, United States), D. Jackson (Madison, United States), N. Li (Bridgewater, United States), B. Akinlade (Tarrytown, United States), E. Laws (Bridgewater, United States), L. Mannent (Chilly-Mazarin, France), J. Maloney (Tarrytown, United States), K. Tawo (Bridgewater, United States), F. Khokhar (Tarrytown, United States), M. Hardin (Cambridge, United States), R. Abdulai (Cambridge, United States), D. Lederer (Tarrytown, United States), L. Robinson (Cambridge, United States)
| |